The U.S. Food and Drug Administration plans to encourage testing of medicines that have been around longer than the modern FDA itself, and so have never gotten formal approval. Companies that do the tests are rewarded with licenses that can temporarily give them monopoly pricing power as most rivals are eased or kicked off the market. The result has been a surge in the cost of drugs. Aaron Kesselheim (Brigham and Women’s) is quoted.
Trending News
Patient Who Received Pig Kidney Becomes First To Progress to Human Kidney Transplant
Study shows xenotransplantation can serve as a bridge for patients with end-stage kidney disease
Harvard, Yale Researchers Awarded $46 Million Grant To Study Autism, Brain Development
Leads include stem cell biologist Paola Arlotta, biomedical AI researcher Marinka Zitnik
Mammalian Genes Can Combine To Make Previously Unknown mRNAs, Proteins
Chimeric mRNA could provide new insight into difficult-to-treat diseases